Apr. 16 - New GI motility therapy for patients with inflammatory bowel disease
Researchers at the University of Calgary have identified a novel therapeutic strategy to preserve gastrointestinal (GI) motility in patients suffering from inflammatory bowel disease (IBD).
IBD and other GI tract disorders are associated with abnormal gut motility where muscle contractions in the intestinal walls become irregular resulting in food not passing through the intestine properly. This leads to painful and debilitating symptoms including chronic GI dysfunction.
Pre-clinical experiments in mouse models of Crohn’s disease show the effectiveness of the technology in preventing inflammation-induced enteric neurotoxicity and preserving proper GI motility and function.
This new therapy is available for licensing through Innovate Calgary. Learn more